复方甘草酸单胺辅助治疗初治肺结核并存慢性乙型肝炎临床观察  

Clinical observation on the clinical efficacy of compound Glycyrrhizin in the treatment of new pulmonary tuberculosis complicated with chronic hepatitis B

作　　者：翁丽珍[1] 朱玉芳[1] 陈淑琴[1] 李学玲[1] 毛雅云[1] 刘坦业[1] 

机构地区：[1]福建医科大学福州肺科医院临床教学医院,福州350008

出　　处：《中国防痨杂志》2007年第5期419-422,共4页Chinese Journal of Antituberculosis

基　　金：福州市科技计划项目(2004-66)

摘　　要：目的观察复方甘草酸单胺(美能)辅助治疗初治肺结核并存慢性乙型肝炎的临床疗效与不良反应。方法将60例初治肺结核并存慢性乙型肝炎者分为治疗组与对照组各30例,2组均在有效抗结核治疗基础上,治疗组加用美能;对照组给予还原型谷胱甘肽。结果治疗2个月时,治疗组肝功能改善总有效率76.7%,对照组为46.7%(P<0.05),治疗组临床症状和体征消失率、明显改善率分别为40%和56.7%,对照组为26.7%和46.7%,两者比较有显著差异。治疗组不良反应少。结论美能在初治肺结核并存慢性乙型肝炎患者治疗过程中能有效改善肝功能。Objective To observe the clinical efficacy and the adverse reactions of Compound Glycyrrhizin （Stronger Neo-Minophagen C） in the treatment of new pulmonary tuberculosis complicated with chronic Hepatitis B. Methods Sixty cases of new pulmonary tuberculosis complicated with chronic Hepatitis B were randomly divided into the treatment group （30 cases） and control group （30 cases）. The both groups were treated with effective antitubercuolsis drugs. The treatment group was treated with Stronger Neo-Minophagen ,C, while the control group took glutathione. Results After two months treatment, the total effective rate of liver function improvement was 76.7 % in the treatment group, and 46.7 % （ P 〈 0.05 ） in the control group. The rates of clinical symptom and physical sign disappearance as well as distinct amelioration were 40 % and 56.7 % in the treatment group, and 26.7 % and 46.7 % in the control group, respectively. There were notable differences between the treatment group and the control group in the above mentioned aspects. Adverse reactions were rarely found. Conclusion Stronger Neo-Minophagen C is effective and reliable in improving liver function of patients suffering from new pulmonary tuberculosis complicated with chronic Hepatitis B during antituberculosis chemotherapy.

关 键 词：肺结核 药物治疗 慢性乙型肝炎 复方甘草酸单胺 

分 类 号：R512.62[医药卫生—内科学] R521[医药卫生—临床医学]